Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
COSMO Pharmaceuticals N.V. ( (CH:COPN) ) just unveiled an announcement.
Cosmo Pharmaceuticals has entered a strategic R&D collaboration with Amsterdam UMC and Eindhoven University of Technology to develop and clinically validate an AI-based detection system for early neoplasia in Barrett’s esophagus. The project aims to extend the GI Genius platform from colorectal cancer prevention into upper gastrointestinal indications, addressing a major challenge in early detection during endoscopy.
The partners will pool clinical, imaging, and technical expertise to build one of the most comprehensive curated datasets in Barrett’s esophagus and to train and validate new AI algorithms in specialized centers. Cosmo will oversee industrialization and regulatory pathways for global markets, reinforcing its Vision 2030 strategy and strengthening its position in AI-supported endoscopy by expanding the GI Genius ecosystem to multiple GI diseases.
The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF134.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.
More about COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals is a Dublin-based life sciences company specializing in MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing. It designs and manufactures advanced medical solutions, including the GI Genius platform for AI-assisted endoscopy, serving global pharmaceutical and medical technology partners through operations in Europe and the United States.
Average Trading Volume: 72,293
Technical Sentiment Signal: Buy
Current Market Cap: CHF1.85B
Find detailed analytics on COPN stock on TipRanks’ Stock Analysis page.